Cary M. Looney

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Clinical MAPPs: a personalized healthcare-driven assay for the direct identification of potential T cell epitopes in patients.

Clinical MAPPs: a personalized healthcare-driven assay for the direct identification of potential T cell epitopes in patients.

Journal: Frontiers in immunology

Published: May 12, 2026

Correspondence on: 'CD19-CAR T-cell therapy induces deep tissue depletion of B cells' by Tur et al.

Correspondence on: 'CD19-CAR T-cell therapy induces deep tissue depletion of B cells' by Tur et al.

Journal: Annals of the rheumatic diseases

Published: August 27, 2025

Elucidation of B-cell specific drug immunogenicity liabilities via a novel ex vivo assay.

Elucidation of B-cell specific drug immunogenicity liabilities via a novel ex vivo assay.

Journal: Frontiers in immunology

Published: March 07, 2025

Internalization of therapeutic antibodies into dendritic cells as a risk factor for immunogenicity.

Internalization of therapeutic antibodies into dendritic cells as a risk factor for immunogenicity.

Journal: Frontiers in immunology

Published: April 15, 2024

Development and characterization of dendritic cell internalization and activation assays contributing to the immunogenicity risk evaluation of biotherapeutics.

Development and characterization of dendritic cell internalization and activation assays contributing to the immunogenicity risk evaluation of biotherapeutics.

Journal: Frontiers in immunology

Published: April 15, 2024

Expanding the MAPPs Assay to Accommodate MHC-II Pan Receptors for Improved Predictability of Potential T Cell Epitopes.

Expanding the MAPPs Assay to Accommodate MHC-II Pan Receptors for Improved Predictability of Potential T Cell Epitopes.

Journal: Biology

Published: August 27, 2023

Development of a novel, highly sensitive assay for quantification of minimal residual B cells in autoimmune disease and comparison to traditional methods across B-cell-depleting agents.

Development of a novel, highly sensitive assay for quantification of minimal residual B cells in autoimmune disease and comparison to traditional methods across B-cell-depleting agents.

Journal: Clinical immunology (Orlando, Fla.)

Published: November 02, 2022

Validation of a Dendritic Cell and CD4+ T Cell Restimulation Assay Contributing to the Immunogenicity Risk Evaluation of Biotherapeutics.

Validation of a Dendritic Cell and CD4+ T Cell Restimulation Assay Contributing to the Immunogenicity Risk Evaluation of Biotherapeutics.

Journal: Pharmaceutics

Published: October 31, 2022

Obinutuzumab Effectively Depletes Key B-cell Subsets in Blood and Tissue in End-stage Renal Disease Patients.

Obinutuzumab Effectively Depletes Key B-cell Subsets in Blood and Tissue in End-stage Renal Disease Patients.

Journal: Transplantation direct

Published: October 31, 2022

B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial.

B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial.

Journal: Annals of the rheumatic diseases

Published: June 03, 2021

Regulation and Role of αE Integrin and Gut Homing Integrins in Migration and Retention of Intestinal Lymphocytes during Inflammatory Bowel Disease.

Regulation and Role of αE Integrin and Gut Homing Integrins in Migration and Retention of Intestinal Lymphocytes during Inflammatory Bowel Disease.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: March 08, 2021

Showing 1-11 of 11

Last Updated: 09/26/2026